Interferon, interleukin 2 in metastatic cancer of the kidney
Extra, J.M.
Pathologie-Biologie 37(9): 1069
1989
ISSN/ISBN: 0369-8114 PMID: 2608347 Document Number: 339688
Document emailed within 1 workday
Related Documents
Negrier, S.; Douillard, J.-Y.; Gomez, F.éd.ér.; Lasset, C.; Chevreau, C.; Escudier, B. 2002: Interleukin-2 and interferon in metastatic kidney cancer. Experience of the French Immunotherapy Group Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 12(2): 213-218Jurincic-Winkler, C.; Horlbeck, R.; Klippel, K.F. 1993: Combination therapy with recombinant interferon alpha-21 (rIFN alpha 2a) and recombinant interleukin 2 (rIL-2) in metastatic renal cell cancer Wiener Klinische Wochenschrift 105(10): 271-276
Sibert, L.; Planet, M.; Kuhn, J.M.; Annoot, M.; Boillot, B.; Grise, P. 1994: Hypothyroidism and immunotherapy using interferon or interleukin for metastatic renal adenocarcinoma Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 4(4): 582-587
Legha, S.S. 1997: Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy Seminars in Oncology 24(1 Suppl 4: S39-S43
Proebstle, T.M.; Scheibenbogen, C.; Sterry, W.; Keilholz, U. 1996: A phase II study of dacarbazine, cisplatin, interferon-alpha and high-dose interleukin-2 in 'poor-risk' metastatic melanoma European Journal of Cancer 32a(9): 1530-1533
Keilholz, U.; Scheibenbogen, C.; Stoelben, E.; Saeger, H.D.; Hunstein, W. 1994: Immunotherapy of metastatic melanoma with interferon-alpha and interleukin-2: pattern of progression in responders and patients with stable disease with or without resection of residual lesions European Journal of Cancer 30a(7): 955-958
Kierszenbaum, F.; Lopez, H.M.; Sztein, M.B. 1996: Trypanosoma cruzi downregulates the production of interleukin-2, interferon-gamma, interleukin-4 and interleukin-5 by activated human lymphocytes Journal of Parasitology 82(4): 652-656
Wissing, K.M.; Desalle, F.; Abramowicz, D.; Willems, F.; Leo, O.; Goldman, M.; Alegre, M.L. 1999: Down-regulation of interleukin-2 and interferon-gamma and maintenance of interleukin-4 and interleukin-10 production after administration of an anti-CD3 monoclonal antibody in mice Transplantation 68(5): 677-684
Yamasaki, T.; Kagawa, T.; Takamura, M.; Moritake, K. 1995: Pharmacokinetics of intratumoral interferon-gamma activity following subcutaneous administration of recombinant interferon-gamma in a patient with metastatic brain tumor derived from renal cancer No Shinkei Geka. Neurological Surgery 23(2): 169-173
Sznol, M.; Clark, J.W.; Smith, J.W.; Steis, R.G.; Urba, W.J.; Rubinstein, L.V.; VanderMolen, L.A.; Janik, J.; Sharfman, W.H.; Fenton, R.G. 1992: Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma Journal of the National Cancer Institute 84(12): 929-937
Maoleekoonpairoj, S. 1995: Combination 5-fluorouracil (5-FU) and alpha interferon (IFN) in metastatic colorectal cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 22(Suppl 3): 285
Négrier, S.; Mercatello, A.; Coronel, B.; Merrouche, Y.; Bret, M.; Blay, J.Y.; Thiesse, P.; Clavel, M.; Moskovtchenko, J.F.; Philip, T. 1993: Immunotherapy of metastatic kidney cancer Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 3(2): 187-194
Takehara, K.; Koga, S.; Nishikido, M.; Kanetake, H.; Hayashi, T.; Hara, S.; Ayabe, H.; Saito, Y. 1999: Breast cancer metastatic to the kidney Anticancer Research 19(6c): 5571-5573
Lissoni, P.; Rovelli, F.; Baiocco, N.; Tangini, G.; Fumagalli, L. 2001: A phase Ii study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic renal cell carcinoma progressing on interleukin-2 alone Anticancer Research 21(1b): 777-779
Dutcher, J.P. 2011: High-dose interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma: still the standard Oncology 25(5): 427-428
Qi, T.; Xie, L.; Wang, Y.; Wang, J.; Chen, H.; Zhou, L. 2002: Dynamic variation of serum and stool level of interleukin-2, interleukin-6 and interferon-alpha in children with rotavirus enteritis and its relation to clinical manifestations Zhonghua Shi Yan he Lin Chuang Bing du Xue Za Zhi 16(3): 270-273
Cortés, J.; Uriz, A.; Terrasa, J.; Rifá, J.; Rosselló, J.J.; Llompart, M. 1986: Ovarian cancer metastatic to the kidney: case report European Journal of Gynaecological Oncology 7(3): 206-209
Herrmann, F.; Gebauer, G.; Lindemann, A.; Brach, M.; Mertelsmann, R. 1989: Interleukin-2 and interferon-gamma recruit different subsets of human peripheral blood monocytes to secrete interleukin-1 beta and tumour necrosis factor-alpha Clinical and Experimental Immunology 77(1): 97-100
Lissoni, P.; Mengo, S.; Bucovec, R.; Brivio, F.; Fumagalli, L.; Tancini, G.; Gardani, G.S. 2003: Clinical and biological effects of interleukin-2 with or without a concomitant administration of granulocyte-macrophage colony-stimulating factor in metastatic cancer patients In Vivo 17(1): 73-75
Krown, S.E.; Mintzer, D.; Cunningham-Rundles, S.; Niedzwiecki, D.; Krim, M.; Einzig, A.I.; Gabrilove, J.L.; Shurgot, B.; Gessula, J. 1987: High-dose human lymphoblastoid interferon in metastatic colorectal cancer: clinical results and modification of biological responses Cancer Treatment Reports 71(1): 39-45